Hosono Tomomi, Kondo Aiko, Kambayashi Yasuyuki, Homma Masato
Pharmacy Department, University of Tsukuba Hospital.
Department of Pharmaceutical Sciences, Faculty of Medicine, University of Tsukuba.
Yakugaku Zasshi. 2017;137(8):999-1003. doi: 10.1248/yakushi.16-00270.
Several case studies have reported a possible drug interaction between warfarin and tramadol where tramadol coadministration enhanced the antithrombotic effects of warfarin. To assess this drug interaction, changes in prothrombin time-international normalized ratio (PT-INR) before and after tramadol coadministration were investigated in patients receiving warfarin. For this study, we examined 54 patients (male/female: 22/32, 68.4±12.7 years) who were being treated with warfarin for deep vein thrombosis, atrial fibrillation, arteriosclerosis obliterans, congestive heart failure, and other vascular diseases. Significant increases in PT-INR were observed 9.5 (1-118) d after coadministration of tramadol (1.81±0.56 vs. 2.47±1.10, p<0.01). Twenty-eight patients (PT-INR increased group) with PT-INR elevation of greater than 0.5 or dose reduction of warfarin after coadministration of tramadol were compared with other groups of patients to find drug interaction risk factors. Logistic regression analysis revealed that lower levels of albumin (3.5 g/dL or less) [odds ratio (OR) 22.1; 95%CI 2.9-169.9]; lower eGFR (50 mL/min or less) (OR 7.7; 95%CI 1.4-42.0); and PT-INR before tramadol coadministration (OR 38.2; 95%CI 3.7-397.6) were characteristic of the PT-INR increased group. These results suggest that tramadol coadministration enhanced the antithrombotic effects of warfarin in patients with higher PT-INR, lower albumin levels and decreased renal function as the risk factors for this drug interaction.
几项病例研究报告了华法林与曲马多之间可能存在药物相互作用,即联合使用曲马多可增强华法林的抗血栓形成作用。为评估这种药物相互作用,对接受华法林治疗的患者在联合使用曲马多前后的凝血酶原时间-国际标准化比值(PT-INR)变化进行了研究。在本研究中,我们检查了54例患者(男/女:22/32,年龄68.4±12.7岁),这些患者因深静脉血栓形成、心房颤动、闭塞性动脉硬化、充血性心力衰竭及其他血管疾病正在接受华法林治疗。联合使用曲马多9.5(1-118)天后观察到PT-INR显著升高(1.81±0.56 vs. 2.47±1.10,p<0.01)。将联合使用曲马多后PT-INR升高大于0.5或华法林剂量减少的28例患者(PT-INR升高组)与其他患者组进行比较,以寻找药物相互作用的危险因素。逻辑回归分析显示,白蛋白水平较低(3.5 g/dL或更低)[比值比(OR)22.1;95%置信区间2.9-169.9];估算肾小球滤过率(eGFR)较低(50 mL/min或更低)(OR 7.7;95%置信区间1.4-42.0);以及联合使用曲马多前的PT-INR(OR 38.2;95%置信区间3.7-397.6)是PT-INR升高组的特征。这些结果表明,联合使用曲马多可增强PT-INR较高、白蛋白水平较低及肾功能下降患者的华法林抗血栓形成作用,这些因素是这种药物相互作用的危险因素。